Urol. praxi. 2020;21(4):150-154 | DOI: 10.36290/uro.2020.037

Role of alpha blockers in treating obstructive uropathy

MUDr. Roman Staněk
Urologické oddělení, Slezská nemocnice Opava

Obstructive uropathy is a term that can be used for clinical and objective conditions, such as upper urinary tract obstructions or subvesical obstructions, i.e. lower urinary tract obstructions. In both cases, alpha blockers are used in pharmacotherapy. This article discusses the role of alpha blockers in treating subvesical obstructions causing lower urinary tract symptoms (commonly abbreviated as LUTS) as well as the use of alpha blockers in treating upper urinary tract obstructions due to urolithiasis.

Keywords: alpha blockers, upper urinary tract obstruction, lower urinary tract symptoms.

Accepted: August 25, 2020; Published: January 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Staněk R. Role of alpha blockers in treating obstructive uropathy. Urol. praxi. 2020;21(4):150-154. doi: 10.36290/uro.2020.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fitzpatrick D, Purves D, Augustine G. Table 20: 2. Neuroscience (3rd ed.). Sunderland, Mass: Sinauer. Chou EC, Capello SA, Levin RM, Longhurst PA (2003). Excitatory α1-adrenergic receptors predominate over inhibitory β-receptors in rabbit dorsal detrusor. J. Urol 2004; 170(6 Pt 1): 2503-2507. Go to original source... Go to PubMed...
    2. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978; 50(7): 551-554. Go to original source... Go to PubMed...
    3. Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan M, Milroy EJ. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 1987; 60(2): 136-142. Go to original source... Go to PubMed...
    4. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148(5): 1467-1474. Go to original source... Go to PubMed...
    5. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154(1): 105-109. Go to original source... Go to PubMed...
    6. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283(15): 1967-1975.
    7. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51(6): 892-900. Go to original source... Go to PubMed...
    8. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 drenoceptors: binding, functional and in vivo studies.Br J Pharmacol 1996; 118(4): 871-878. Go to original source... Go to PubMed...
    9. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37(3): 306-313. Go to original source... Go to PubMed...
    10. Drugs.com, Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia. Retrieved 2008-02-13.
    11. Malin JM, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. BrJ Urol 1970; 42: 171-174. Go to original source... Go to PubMed...
    12. Sigala S, Dellabella M, Milanese G, et al. Evidencefor the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodynamics 2005; 24: 142-148. Go to original source... Go to PubMed...
    13. Purves D, Augustine GJ, Fitzpatrick D, et al. editors. Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001.
    14. Dvořáček J. Kombinovaná léčba benigní hyperplazie prostaty. Urol. praxi 2012; 13(4): 148-153.
    15. Žemličková B, Čechová M. Benigní hyperplazie prostaty - aktuální možnosti farmakoterapie, rizika a limity spojené s léčbou. Urol. praxi 2019; 20(4): 161-165. Go to original source...
    16. Barendrecht MM, et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 2008; 27: 226. Go to original source... Go to PubMed...
    17. Kortmann BB, et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology 2003; 62: 1. Go to original source... Go to PubMed...
    18. Hollingsworth, JM, Rogers MAM, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368: 1171-1179. Go to original source... Go to PubMed...
    19. Lipkin M, Shah O. The Use of Alpha-Blockers for the Treatment of Nephrolithiasis 2006; 8(4): S35.
    20. Hollingsworth JM, Canales BK, Rogers MAM, Sukuma S, Yan P, Kuntz GM, Dahm P. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ 2016; 355: i6112. doi: 10.1136/bmj.i6112. Go to original source... Go to PubMed...
    21. Novák K. Terapie non-neurogenních poruch mikce u mužů. Urol. praxi 2011; 12(3):
    22. Veselský Z, Višňovský, Jurášková B, Macek P, Förstl M, Prošvic P. Volba inhibitoru alfa1 adrenergního receptoru v současné terapii benigní hyperplazie prostaty a hypertenze. Urolog. praxi 2004; 3: 108-111.
    23. Unnikrishnan R, Nima Almassi MD, Khaled Fareed MD. Benign prostatic hyperplasia: Evaluation and medical management in primary care Cleveland Clinic. Journal of Medicine January 2017; 84(1) 53-64. Go to original source... Go to PubMed...
    24. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-1474. Go to original source... Go to PubMed...
    25. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115. Go to original source... Go to PubMed...
    26. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634-2640. Go to original source... Go to PubMed...
    27. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701-1706. Go to original source... Go to PubMed...
    28. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634-2640. Go to original source... Go to PubMed...
    29. Do Kyung Kim, Joo Yong Lee, Jae Hung Jung, Jae Heon Kim, Yoon Soo Hah, Chang Hee Hong, Kang Su. Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis Cho5 Int Neurourol J 2019; 23(1): 56-68. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.